Citizens Bank of West Virginia Receives FHLBank Pittsburgh's 2025 Annual Member Award
This award is presented to member financial institutions that have demonstrated an outstanding commitment to community development. Awardees have also demonstrated exemplary efforts and effective use of FHLBank's community products. This award is FHLBank's highest organizational honor and is presented annually to select FHLBank members in recognition of their commitment to community revitalization. This year's other winner is First Citizens Community Bank in Mansfield, Pennsylvania.
Citizens Bank is a locally owned community bank and primarily serves West Virginians with a comprehensive line of banking, trust and investment products. In 2024, Citizens Bank utilized FHLBank's Home4Good program to support local affordable housing needs, as well as FHLBank's Banking On Business program to help Siler Cycle and Automotive, which specializes in car repairs, including steering, brakes and alignment. The capital helped with purchases, such as computer equipment and tire inventory, as well as routine items, including payroll and office supplies. Citizens Bank's use of FHLBank programs has benefited their stakeholders and contributed to their selection as a 2025 Pillars of the Community Award winner.
Click here to learn more about Citizens Bank, the 2025 Pillars of the Community Award recognition, and their incredible community work.
About Citizens Bank of West Virginia
Citizens Bank of West Virginia, with $678 million in assets, provides integrated financial services including retail and commercial banking, wealth management, and mortgage services from six offices in Elkins, Parsons, Beverly, Snowshoe, Buckhannon and New Martinsville. The bank is a wholly owned subsidiary of Citizens Financial Corp. (OTC: CIWV). Citizens Bank was recognized for the fourth consecutive year by American Banker magazine in the Top Performing Publicly Trading Community Banks Under $2 Billion of Assets in the Nation, ranking 25th on the prestigious Top 100 list and 1st among WV banks. Citizens is also named to Newsweek's America's Best Banks list as the Best Small Bank in WV, ranked 16th as one of the Best Banks to Work for in the Country by American Banker, Best of West Virginia Corporate Citizen by WV Living, The Inter-Mountain's People's Choice Best Bank, Mortgage Lender, Customer Service & Employer, SBA WV Community Lender of the Year, and ranked the nation's no. 9 top lender by Independent Community Bankers of America (ICBA) in the consumer/mortgage category for banks $300M - $1B in assets and No. 1 as the consumer/mortgage lender in West Virginia in this class. More information is available online at www.citizenswv.com.
About FHLBank Pittsburgh
FHLBank Pittsburgh provides reliable funding and liquidity to its member financial institutions, which include commercial and savings banks, community development financial institutions, credit unions and insurance companies in Delaware, Pennsylvania and West Virginia. FHLBank products and resources help support community lending, housing and economic development. As one of 11 Federal Home Loan Banks established by Congress, FHLBank has been an integral and reliable part of the financial system since 1932. Learn more by visiting www.fhlb-pgh.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
a day ago
- Business Insider
J.P. Morgan Sticks to Their Buy Rating for Suncorp Group (SNMYF)
J.P. Morgan analyst Siddharth Parameswaran maintained a Buy rating on Suncorp Group on August 14 and set a price target of A$21.20. The company's shares closed last Friday at $10.83. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Parameswaran is a 4-star analyst with an average return of 9.2% and a 66.08% success rate. Parameswaran covers the Financial sector, focusing on stocks such as ASX , AMP , and Computershare Limited. In addition to J.P. Morgan, Suncorp Group also received a Buy from Morgan Stanley's Andrei Stadnik in a report issued yesterday. However, on August 14, Citi maintained a Hold rating on Suncorp Group (Other OTC: SNMYF). Based on Suncorp Group's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.35 billion and a net profit of $1.1 billion. In comparison, last year the company earned a revenue of $9.5 billion and had a net profit of $582 million
Business Upturn
2 days ago
- Business Upturn
Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company's innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth. Regen sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market projected to be valued at well in excess of $1 billion annually. HemaXellerate is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation. Advertisement HemaXellerate is comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method to induce a biological response in the patient that heals damaged bone marrow and restores the body's ability to generate healthy blood cells. 'Aplastic anemia patients without access to bone marrow transplantation face limited options,' said Dr. David Koos, Chairman and CEO of Regen BioPharma. 'With FDA clearance to begin clinical trials, HemaXellerate has the potential to redefine the treatment landscape—not just for aplastic anemia but for a wide range of hematological disorders. This is a pivotal moment for our company as we work to deliver life-changing therapies to patients worldwide.' To ensure the trial's success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months. Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity. Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market. Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence. About Regen BioPharma, Inc. Regen BioPharma, Inc. is a publicly traded biotechnology company (OTC ID: RGBP) and (OTC ID: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effect of government regulation, competition and other material risks. CONTACT INFORMATION: Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-722-5505 Phone Email: [email protected] or [email protected] X (formerly twitter): Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Insider
2 days ago
- Business Insider
Ord Minnett Remains a Sell on Westpac Banking (WEBNF)
In a report released today, from Ord Minnett maintained a Sell rating on Westpac Banking, with a price target of A$30.00. The company's shares closed yesterday at $23.00. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In addition to Ord Minnett, Westpac Banking also received a Sell from Morgans's Nathan Lead in a report issued today. However, yesterday, UBS maintained a Buy rating on Westpac Banking (Other OTC: WEBNF). The company has a one-year high of $23.28 and a one-year low of $16.30. Currently, Westpac Banking has an average volume of 3,277. Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of WEBNF in relation to earlier this year.
